Recursion reports Phase 2 FAP data, Sanofi option, Hassan as new chairNov 2Quarterly updateREC-1245Recursion Pharmaceuticals, Inc.
Recursion prices $200M offering, reports Sanofi milestone and TUPELO, DAHLIA dataOct 15Quarterly updateAlector, Inc.REC-1245Updated
Recursion Pharmaceuticals amends Tempus AI data pact and licenses RNA model for oncologySep 21PartnershipRecursion Pharmaceuticals, Inc.
Recursion registers Phase 1/2 trial of REC-7735 in PIK3CA-H1047R solid tumorsSep 14Trial updateREC-7735Recursion Pharmaceuticals, Inc.
Recursion posts Q2 2026 results, Genentech advances first neuroscience targetAug 5Quarterly updateRecursion Pharmaceuticals, Inc.Roche